• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Ther Adv Respir Dis . Arterial lactate as a risk factor for death in respiratory failure related to coronavirus disease 2019: an observational stud

tetano

Editor, Senior Moderator
Ther Adv Respir Dis


. 2023 Jan-Dec;17:17534666231186730.
doi: 10.1177/17534666231186730. Arterial lactate as a risk factor for death in respiratory failure related to coronavirus disease 2019: an observational study

Giorgio Maraziti[SUP] 1 [/SUP], Laura Marchini[SUP] 2 [/SUP], Greta Barbieri[SUP] 3 4 [/SUP], Marco Falcone[SUP] 5 [/SUP], Francesco Corradi[SUP] 3 6 [/SUP], Mara Graziani[SUP] 2 [/SUP], Lorenzo Ghiadoni[SUP] 7 [/SUP], Cecilia Becattini[SUP] 2 [/SUP]



Affiliations
Abstract

Background: Arterial lactate is a recognized biomarker associated with death in critically ill patients. The prognostic role of arterial lactate in acute respiratory failure due to the novel coronavirus disease 2019 (COVID-19) is unclear.
Objectives: We aimed to investigate the prognostic role of arterial lactate levels at admission in patients with COVID-19-related acute respiratory failure.
Design and methods: Cohorts of consecutive patients admitted to nonintensive care units (ICU) at study centers for COVID-19-related respiratory failure were merged into a collaborative database. The prognostic role of lactate levels at admission was assessed for continuous values and values ⩾2.0 mmol/l, and lactate clearance at 24 h through delta-lactate (ΔLac). The study outcome was 30-day in-hospital death. Cox proportional regression model was used to assess independent predictors of the study outcome.
Results: At admission, 14.6% of patients had lactate levels ⩾2 mmol/l. In-hospital death at 30 days occurred in 57 out of 206 patients; 22.3% and 56.7% with normal or ⩾ 2 mmol/l lactate at admission, respectively. The median lactate level was 1.0 [interquartile range (IQR) 0.8-1.3] mmol/l and 1.3 (IQR 1.0-2.1) mmol/l in survivors and nonsurvivors, respectively (p-value < 0.001). After adjusting for age, relevant comorbidities, acidemia, and the severity of respiratory failure, lactate ⩾2.0 mmol/l was associated with in-hospital death (HR 2.53, 95% CI 1.29-4.95, p-value 0.0066), while Δ Lac ⩾0 was not (HR 1.37, 95% CI 0.42-4.49). These results were confirmed in patients with a pO[SUB]2[/SUB]/FiO[SUB]2[/SUB]-ratio (P/F ratio) ⩽300 mmHg.
Conclusions: In our study, increased arterial lactate at admission was independently associated with in-hospital death at 30 days in non-ICU patients with acute respiratory failure related to COVID-19.

Keywords: COVID-19; adult respiratory distress syndrome; lactate; respiratory insufficiency.

 
Back
Top Bottom